Infilea (Clobetasol Propionate)

Clobetasol propionate binds to glucocorticoid receptors inside skin cells, forming a complex that moves into the nucleus and alters gene expression. This suppresses the production of inflammatory mediators, limits immune‑cell infiltration, and slows the proliferation of epidermal cells, resulting in marked anti‑inflammatory and antiproliferative effects on the treated area.

The specific dosing regimen for Infilea is determined by the prescribing clinician based on the severity of the condition, the size of the affected area, and patient factors. The prescriber will provide instructions on the amount to apply, frequency, and duration of therapy, which should be followed precisely.

The safety of clobetasol propionate in pregnancy and lactation has not been definitively established, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made in consultation with a qualified healthcare provider.

To request Infilea, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Infilea delivers clobetasol propionate, one of the most potent class I corticosteroids available for topical use. Compared with lower‑potency steroids such as hydrocortisone or betamethasone, clobetasol provides faster and more pronounced reduction of inflammation and plaque formation, but it also carries a higher risk of local side effects if used improperly.

Infilea should be stored at room temperature, ideally below 25 °C, in its original packaging to protect it from moisture and direct light. Keep the container tightly closed when not in use and avoid exposing the product to excessive heat or humidity, which could affect its stability and efficacy.

Infilea is applied topically to the affected skin area. The prescriber will advise the appropriate amount—usually a thin film— and the frequency, often once or twice daily. Hands should be washed before and after application, and the treated area should be gently patted to allow absorption without rubbing.

Serious risks include skin atrophy, telangiectasia, secondary infections, and systemic effects such as hypothalamic‑pituitary‑adrenal axis suppression, especially with prolonged use over large areas. Patients should be monitored for signs of these complications, and therapy should be discontinued if severe adverse reactions occur.

Infilea is contraindicated in individuals with known hypersensitivity to clobetasol propionate or any formulation component, in untreated bacterial, viral, or fungal skin infections, and in patients with certain skin conditions such as rosacea or perioral dermatitis where corticosteroids may worsen the disease. It should also be avoided on broken skin unless directed by a physician.